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An Evolving Role for Cancer Rehabilitation in the Era of Low-Dose
Lung Computed Tomography Screening
Sean Robinson Smith, MD, Ashish Khanna, MD, Eric M. Wisotzky, MDAbstractLung cancer is the number one cause of cancer-related death worldwide, and is often detected in the later stages. Use of low-
dose chest computed tomography in at-risk patients provides earlier detection and is being adopted as the standard screening
tool, replacing less precise methods of radiography and sputum cytology. In the past, late detection of disease meant that
rehabilitation interventions attempted to salvage function and to improve aerobic capacity to the point where patients could
tolerate the sometimes-extensive oncologic treatment, including lobectomy or pneumonectomy. Earlier detection may shift this
toward more often addressing specific neuromusculoskeletal impairments, such as postthoracotomy pain or peripheral neurop-
athy, as patients with early-stage disease may not be as debilitated by chronic disease or metastases as those with late-stage lung
cancer. Patients with advanced disease, however, will still require rehabilitation interventions, and this fragile population creates
unique challenges. Rehabilitation professionals should look for ways to expand care to lung cancer patients, as both the number of
those treated and the 5-year survival rate are expected to increase.Introduction
Lung cancer is one of the most common cancer
diagnoses worldwide, and remains the number one
cause of cancer-related death in both men and women
[1,2]. During 2016, the incidence of new cases in the
United States was estimated to be 224,400, represent-
ing about 14% of all cancer diagnoses [3]. Approximately
415,000 Americans have a diagnosis of lung cancer, 82%
of whom are age 60 years or older, with the average age
at diagnosis at 70 (less than 2% are younger than 45
years) [4]. Smoking remains the primary risk factor for
developing disease, and nonsmokers who are exposed to
second-hand smoke by living with a smoker have a 20%-
30% increased risk of developing lung cancer over that of
the general population. About 10% of cases arise from
toxic exposure, such as to radon or asbestos [3]. The risk
of developing lung cancer without any of these factors is
unclear. Of note, the majority of people with a history
of lung cancer have had their diagnoses made within the
past 5 years.
Primary lung carcinoma is a heterogeneous group
of tumor subtypes, with the most important distinc-
tion being between small-cell and nonesmall-cell lung1934-1482/$ - see front matter ª 2017 by the American Academy of Physi
http://dx.doi.org/10.1016/j.pmrj.2017.06.005cancer (NSCLC). Treatment of NSCLC often involves a
combination of surgery, chemotherapy, and/or radia-
tion, whereas small-cell lung cancer often does not
involve surgery unless there are focal, large areas of
tumor burden in a location amenable to resection [5]. In
those with early-stage lung cancer, surgical resection of
the tumor is typically the first aspect of oncologic
management [6].
The diagnosis of lung cancer is, unfortunately, often
late, as patients may be asymptomatic with early-stage
lung cancer, and up to two-thirds of patients have
metastases at the time of diagnosis [7]. Furthermore,
the stage at diagnosis is closely associated with survival,
with a 5-year survival of only 6% for patients with me-
tastases present on initial diagnosis, compared with 85%
for patients with stage IA disease [8]. Only about 15% of
patients are diagnosed with stage I disease [9,10].
Recommendations for lung screening vary by organi-
zation, but most generally agree that testing should be
administered in individuals 55-74 years of age with a
smoking history of 30 pack-years (defined as “heavy
smoking”) and who either continue to smoke or have
quit within the past 15 years. Additional recommenda-
tions include screening patients with a smoking historycal Medicine and Rehabilitation
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as environmental exposure to hazardous chemicals
(other than second-hand smoke) [11]. Screening has
generally consisted of radiography and/or sputum
cytology, with computed tomography (CT) reserved for
patients with suspicious but inconclusive findings on
these modalities [12].
Due to technological advances and the low rate of
early disease detection, in 2014 the US Preventative
Services Task Force recommended annual screening for
lung cancer with low-dose computed tomography
(LDCT) in adults 55 to 80 years of age who have a
smoking history of 30 pack-years and currently smoke or
have quit within the past 15 years [13]. LDCT uses
approximately 20% less radiation than traditional CT
screening, making this protocol safer for patients who
may need serial imaging [14]. These guidelines have
resulted in Medicare coverage of LDCT for patients
meeting the aforementioned criteria.
The largest trial looking at the benefits of lung
screening, the National Lung Screening Trial (NLST),
showed a reduction in lung cancer mortality of 16% and
a reduction in all-cause mortality of 6.7% [14]. The use
of alternative and more aggressive screening criteria
using LDCT are being investigated, potentially prevent-
ing another 16,000 additional deaths because of
improved identification of at-risk patients [15,16]. Mul-
tiple studies continue to evaluate the efficacy of LDCT
screening in an effort to improve specificity, to improve
detection, to save costs, and reduce mortality [9].
Earlier detection through LDCT has the potential
to increase the cure rate of lung cancer through
earlier detection and to reduce treatment-associated
morbidity due to a smaller tumor burden at the time
of diagnosis [9]. It also may change the approach to
rehabilitation of lung cancer patients. Rehabilitation
interventions often help to optimize a patient for
oncologic treatment including surgery, and to manage
symptoms such as pain and weakness. With earlier
detection, rehabilitation programs may have more
opportunities to prevent and to manage symptoms and
functional deficits throughout a longer timeframe, and
perhaps more often into long-term survivorship.
Symptoms and Rehabilitation Needs of Lung Cancer
Patients
Lung cancer and its treatment have the poten-
tial to cause significant symptom burden due to
worsening pain, dyspnea, fatigue, cognitive deficits,
impaired balance, depression, and other symptoms
that contribute to a decrease in health-related quality
of life (HRQoL) [17,18]. When combined with potential
debility from chronic illness such as chronic obstructive
pulmonary disease (COPD), diabetes, and peripheral
vascular disease, these symptoms can have a negative
impact on function and social role [19]. Physical activityand quality of life are lower in patients with NSCLC
compared to healthy controls [20], and low physical
activity [21] and HRQoL [22] are negative prognostic
factors for survival. In advanced stages, metastases to
bones [23] and the central nervous system [24] may
cause functional decline due to neurologic deficits and
pain, necessitating rehabilitation intervention to reduce
symptom burden.
The surgical treatment for lung cancer can be dele-
terious to patients’ function, with surgery typically
consisting of lobectomy or pneumonectomy for NSCLC
patients with locoregional disease. Although both
modalities lead to increased dyspnea and short-term
worsening of pain and physical function, patients who
undergo lobectomy have a reduced burden and duration
of symptoms compared to pneumonectomy patients.
Those undergoing pneumonectomy may never return to
preoperative baseline in physical function, and also
frequently experience dyspnea and/or shoulder pain
[25,26]. In addition, exercise capacity is decreased in
lung cancer patients in general and further by surgery
[21]. The larger the resected disease, the more impact
that surgery appears to have on HRQoL, and more than
20% of patients report having 3 or more severe symp-
toms after surgery [27,28]. This suggests that earlier
detection of smaller disease with LDCT may reduce the
negative impact of surgery.
Extensive disease and/or premorbid chronic illness
may also increase the risk of negative outcomes after
surgery, including prolonged hospital stays and unan-
ticipated readmissions. In a survey of 11,500 patients
undergoing tumor resection, Hu et al found that
approximately 13% of lung cancer patients were read-
mitted to the hospital within 90 days for complications
from surgery. Of those who were readmitted, there was
a 6-fold increase in 90-day mortality. The most common
readmitting diagnoses were respiratory insufficiency,
pneumonia, pneumothorax, and cardiac complications
[29]. This again highlights the potential benefits of early
diagnosis, as chronic comorbidities may be less severe in
patients with early-stage disease.
Chemotherapy, which often follows surgery and
consists of platinum-containing antineoplastic agents,
can contribute to peripheral neuropathy, causing pain
and gait abnormalities as well as cognitive deficits.
Patients who receive chemotherapy have worse HRQoL
at 3-months postoperatively compared to those without
[30], and symptoms of neuropathy often did not abate
over 2.5 years of follow-up in one longitudinal study
[31].
Furthermore, radiation also has potentially nega-
tive effects, with pneumonitis and dyspnea being
the most common short- and long-term complica-
tion, and extensive fibrosis of the lung parenchyma and
surrounding neuromusculoskeletal structures being a
possible late effect [32]. It is unclear whether the
incidence of radiation fibrosis would decrease with
S409S.R. Smith et al. / PM R 9 (2017) S407-S414the earlier detection of disease and potentially
increased use of stereotactic body radiation therapy, a
more precise method of administering radiation that
can be used for smaller tumors and that uses less total
radiation dosing. In the setting of brain metastases,
whole-brain radiation therapy is also a predictor for
development of impaired mobility [24]. Of note,
patients receiving chemotherapy and/or radiation
therapy self-report less physical activity compared to
long-term lung cancer survivors and those who have
recently undergone surgery [33]. It is unclear whether
earlier detection of disease through the use of LDCT
would obviate the need for chemoradiation therapy.
Pain is perhaps the most distressing symptom in lung
cancer patients, with up to 92% of survivors 1-6 years
postoperative reporting some level of pain [34]. One
source of pain is post-thoracotomy pain, which is
thought to be due to injury of the intercostal nerve(s)
during surgery, may be acute or chronic, and is often
neuropathic in nature. Post-thoracotomy pain may be
the most common postoperative source of pain [35], and
it affects approximately 50% of lung cancer patients who
have lung surgery, with about 5% of patients developing
chronic, severe, and disabling pain [36]. Rehabilitation
interventions aim to reduce neuropathic pain, to pre-
serve pulmonary hygiene during periods of severe pain
that prevent deep breathing, and to progressively
improve mobility in patients whose function is compro-
mised by the pain.
Rehabilitation Interventions for Lung Cancer: A
Changing Role With Earlier Detection
Rehabilitation in lung cancer may be performed at
any time along the continuum of care, and traditionally
involves strengthening muscles of respiration, aerobic
conditioning, strategies for energy conservation, as well
as management of pain and other symptoms. Rehabili-
tation before oncologic care, often referred to as pre-
habilitation, may also be used to optimize patient
function before treatment or to improve patients’ res-
piratory and/or performance status to the point at
which they are candidates for surgery or chemotherapy.
To our knowledge, prehabilitation has never been
directly compared to postsurgical rehabilitation in lung
cancer patients, but either approach may confer a
benefit to the patient, depending on the stage and type
of disease and on the patient’s premorbid physical
health.
Numerous studies have found benefits in rehabilita-
tion of lung cancer patients, particularly improved
walking distance and patient-reported symptoms in
early-stage lung cancer, but relatively few studies have
looked at exercise and rehabilitation in advanced
lung cancer [37]. This is despite the fact that patients
with advanced lung cancer have significant func-
tional impairment and musculoskeletal comorbiditiesand often desire rehabilitation services [38]. In fact,
patients have been shown to prefer palliation of symp-
toms and rehabilitation to improve HRQoL even if it
means a trade-off with survival [39], and HRQoL is
directly linked to symptom burden [40] and physical
function [41] in lung cancer patients. Although lung
cancer patients and their families are generally sup-
portive of rehabilitation interventions, they may not be
comfortable performing a self-directed program. This is
true particularly in patients with advanced disease,
suggesting that a structured rehabilitation program is
needed [42].
Postsurgical pulmonary rehabilitation has been shown
to improve various measures of pulmonary and physical
function, particularly when a high-intensity aerobic con-
ditioning approach is tolerated by patients [43]. Edvard-
sen et al found that a 20-week intensive regimen starting
5-7 weeks after lung cancer resection improved exercise
tolerance, functional fitness, muscle mass, and strength.
For patients with early-stage tumors receiving curative
surgery, postoperative rehabilitation helps to improve
both pulmonary and gross physical function [44] and to
reduce distress [45], and should be considered. Other
prospective trials without a control arm suggest a benefit
of postoperative rehabilitation improving physical func-
tion in patients with more advanced disease [46-48].
Unfortunately, rehabilitation after surgery or
chemotherapy is not always successful in improving
physical function or quality of life. This is in part due to
the myriad comorbidities in lung cancer patients,
including COPD and musculoskeletal pain. For example,
Stigt et al found that, in a randomized controlled trial of
patients with advanced lung cancer undergoing reha-
bilitation consisting of exercise, pain management, and
social work support, Six-Minute Walk Test (6MWT) dis-
tance was increased by 35 m compared to that of con-
trols, but pain was worse and quality of life was no
better [49]. This corroborates findings from a similar
study that did not provide pain management or psy-
chosocial support, and that did not even find improve-
ment in the 6MWT results compared to those in controls
[50]. Another study found that postoperative pulmonary
rehabilitation alone does improve physical activity, but
not to the patients’ preoperative baseline [51]. These
findings suggest that when disease is detected late,
postoperative rehabilitation interventions may be less
effective. With earlier detection through the use of
LDCT, rehabilitation interventions may be more effec-
tive and therefore presumably may be used more.
Finally, rehabilitation interventions are also needed
for specific impairments, such as post-thoracotomy pain,
for which pharmacologic [52,53] and procedural
interventions [54,55] administered by a physiatrist may
reduce symptom burden. Other musculoskeletal condi-
tions associated with lung cancer, includingmanagement
of the malignant spine, would benefit from physiatric
management [56].
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Oncologic Treatment and to Improve Outcomes
Prehabilitation, a multimodal intervention to prepare
a patient for upcoming treatment, is an important
intervention to improve physical function and to reduce
symptom burden after surgery, and may be more
effective than postoperative rehabilitation alone. A
recent subject matter expert panel led by Carli and
Silver concluded that in addition to aerobic exercise,
prehabilitation before lung cancer surgery should
consist of nutrition optimization with an emphasis on
protein supplementation and glycemic control, as well
as a smoking cessation program to optimize surgical
outcomes [57]. A recent meta-analysis by Garcia et al of
prehabilitation in lung cancer patients before surgery
found that there appears to be a benefit in pulmonary
function as measured by forced vital capacity (FVC) and
forced expiratory volume in 1 second (FEV1), as well as
in reducing postoperative complications and length of
stay [58]. Given the heterogeneity of outcome measures
as it related to HRQoL, gross physical function, and
exercise capacity, this analysis was unable to assess the
impact of prehabilitation on HRQoL.
In reviewing individual studies that the meta-analysis
by Garcia et al evaluated, however, it is apparent that
prehabilitation does improve both physical function and
HRQoL in lung cancer patients, albeit with incon-
sistent and varying outcome measures that render
meta-analysis inconclusive [44,59-61]. For example, one
randomized controlled study assessed lung cancer pa-
tients who underwent 4 weeks of preoperative
pulmonary rehabilitation consisting of breathing and
aerobic exercise compared to patients receiving
routine chest physical therapy, and found that the
prehabilitation group had improved 6MWT distance
(P < .05), FVC (P < .05), maximal inspiratory and expi-
ratory pressure (P < .05), lower postoperative morbidity
(P ¼ .01), length of stay (P ¼ .04), and days with chest
tubes in place (P ¼ .03) [62]. This study specifically
looked at patients with premorbid pulmonary comor-
bidities such as COPD, showing that aggressive pre-
habilitation is able to improve function even in lung
cancer patients with chronic illness.
A similar controlled study looked at NSCLC patients
with moderate-to-severe COPD receiving prehabilitation
before surgery compared to no intervention, and also
found that the intervention group had fewer chest tube
days (P ¼ .04) and that the decline in length of stay
postoperatively approached statistical significance
(P ¼ .058) [63].
Finally, and perhaps most significant, lung cancer
patients whose pulmonary function was so poor sec-
ondary to COPD such that surgery was too high risk and
who underwent pulmonary prehabilitation showed
improvement to the point where they were able to
tolerate and eventually to undergo surgical resection ofstage I and stage II tumors [64], demonstrating the
potentially lifesaving role of prehabilitation. This
underscores the value of prehabilitation in patients with
premorbid chronic disease, and how this may be an
essential component of care, particularly given that
postoperative rehabilitation alone may not be adequate
in improving function. With the advent of LDCT, there
will likely be more patients whose cancer is diagnosed in
earlier stages, thus increasing the need for pre-
habilitation services to prepare these patients for sur-
gery. Before LDCT, cancer diagnoses in these patients
may have been made at later stages, and therefore
surgery would not have been an option and pre-
habilitation not indicated. By diagnosing these patients
with cancer earlier through LDCT, prehabilitation has
the potential to be lifesaving and should be considered
as an essential component of lung cancer oncologic
treatment, improving access to surgery and potentially
survival outcomes.
In addition to lowering postoperative complications,
prehabilitation may reduce postoperative length of
stay. Weinstein et al found that, in lung cancer patients,
exercise capacity as measured by treadmill-based
physical activity was inversely related to postoperative
length of stay, even after controlling for method of
surgery, gender, presence of dyspnea, and smoking
history (P < .003) [65]. When exercise capacity was
poor, length of stay nearly doubled. This is of particular
importance, not just in reducing morbidity, but in
lowering health care costs and improving health care
efficiency, given the changing health care landscape to
reward care quality and use of bundled payment
models. Prehabilitation may prove to be a cost-effective
rehabilitation intervention, and LDCT may allow earlier
intervention and potentially less morbidity and more
cost savings, an increasingly important aspect of care as
insurance payors switch to quality-based care models.
For patients without chronic disease such as COPD,
undergoing prehabilitation before tumor resection may
be challenging because of the importance of beginning
oncologic treatment as soon as possible. Nevertheless, a
randomized controlled study comparing usual care to
patients undergoing just a 1-week prehabilitation
course consisting of respiratory muscle training, car-
diovascular exercise, education, and bronchodilators (as
needed) found that prehabilitation led to improved
dyspnea, Thoracoscore (a measure used to predict
postoperative mortality and complications), and per-
formance status. Compared to usual care, patients who
went through 1 week of prehabilitation had fewer
postoperative complications (37.5% to 5.3%, P < .015)
and no mortality (compared to 11.1% in the control arm,
P ¼ .05) [66]. If even a 1-week course of prehabilitation
is untenable, pulmonary rehabilitation postoperatively
but during adjuvant radiation and chemotherapy was
shown to improve FVC and FEV1 (P ¼ .0096 and
P < .0001, respectively), but the benefit was lower in
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rehabilitation interventions would be even more im-
pactful were these patients to undergo prehabilitation
for a short time before surgery [67]. Tokarski et al
corroborated findings from this study by observing that
rehabilitation during adjuvant chemotherapy improved
pulmonary function (P < 0.05) [68].
Although helpful for patients with comorbidities such
as COPD, the utility of prehabilitation interventions for
early-stage tumors is not entirely clear. For example,
not all stage I lung cancer patients need to undergo
surgery and chemoradiation therapy immediately upon
detection, creating uncertainty as to when and how a
rehabilitation program is best implemented. Progres-
sion of nonsolid, malignant ground glass nodules is rare,
with one study finding a 100% survival rate of patients
with these ground glass nodules at 6.5 years [69].
Although this may open an opportunity for pre-
habilitation as patients diagnosed with early disease are
expected to increase in number with LDCT, these
patients may not undergo surgery for some time and
may not have significant comorbidities necessitating
intervention. In addition, disease may also be moni-
tored for some time, as one study found that LDCT
screening was associated with a 23% false-positive rate
for even advanced stage disease, meaning that although
LDCT screening is being implemented and improved
upon, treatment may be on hold for some patients
whose diagnosis is unclear and who are undergoing
active surveillance [70]. Nevertheless, programs to
optimize fitness and function in these patients may
reduce morbidity, should disease ever progress and/or
treatment be needed, and patients will need to undergo
active surveillance to ensure that they are not declining
functionally or developing pain.
Survivorship
Five-year survival rates have increased in NSCLC
patients from 11.4% in 1975 to 17.3% in 2009, with rates
increasing to nearly 40% in patients with localized dis-
ease [71,72]. The use of LDCT should improve survival
through earlier detection, potentially creating a large
population of patients with survivorship needs in a
cohort that previously had lower survival rates
compared to patients with other tumor types.
Lung cancer survivors experience lasting effects
of both the disease and treatment, with lower HRQoL
found in 35% of patients 5 years after completion
of treatment [73], and 60% of long-term survivors
reporting at least one chronic, symptomatic comorbidity
[74]. Compared to controls who were never diagnosed
with lung cancer, long-term survivors report lower
physical health, even if their cancer was detected early
[75] and two-thirds of long-term NSCLC survivors do not
meet national physical activity recommendations [76].
The most common physical symptoms experienced bylong-term NSCLC survivors include impaired respira-
tion, fatigue, neuropathic pain, and post-thoracotomy
pain [17].
As described previously, exercise-based rehabilita-
tion interventions may improve physical function and
reduce symptoms related to dyspnea and fatigue. In
long-term survivors, however, the benefits of these
interventions are less clear. Yang et al found that
exercise improved HRQoL in 5-year NSCLC survivors,
despite the fact that symptom burden was not reduced
[70]. In addition, self-reported physical activity in lung
cancer survivors improves physical, emotional, and
mental well-being, although it has no impact on disease
recurrence [33].
Furthermore, impairment-driven rehabilitation that
addresses specific problems in long-term lung cancer
survivorsdsuch as chronic post-thoracotomy pain,
shoulder pain, and peripheral neuropathydmay be
more important in improving function and reducing
distress than general exercise programs, which appear
to improve HRQoL but not reduce symptoms [77]. With
the use of LDCT screening, patients’ premorbid health
may be better than in patients whose diagnoses were
made in previous years, given earlier disease detection,
allowing physiatrists and other members of the cancer
rehabilitation team to focus on particular problems in
patients with relatively preserved general physical
function and exercise capacity.
Finally, long-term survivors also experience consid-
erable psychosocial distress, including depression and
anxiety related to their disease, and subsequent decline
in function, with at least 40% of NSCLC survivors
expressing distress [78]. A survivor’s social role is often
affected, with lung cancer patients having the highest
rate of leaving the workplace of all cancer patients
[79,80]. This chronic symptom burden, along with the
increased focus on management of survivorship needs
including rehabilitation needs [81,82], creates an
expanded role for rehabilitation interventions to restore
function and to address needs over a potentially longer
period of time than before LDCT.
In addition to psychosocial support services and
interventions by trained rehabilitation psychologists to
address the impact of reduced function on survivors’
emotional well-being, walking and exercise programs
also have the potential to reduce distress. One ran-
domized controlled trial of a home-based walking pro-
gram found that survivors still symptomatic from lung
cancer and/or its treatment had reduced anxiety
and depression compared to controls [83]. Symptoms of
severe anxiety may increase perceived dyspnea, so
techniques to manage anxiety may reduce the effects of
dyspnea [84]. The impact of LDCT on survivors’
emotional health remains to be seen; however, with
presumably more long-term survivors, these problems
will likely become more prevalent and will open
up opportunities for physiatrists to provide multiple
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The use of LDCT for lung screening presents an
opportunity for increased rehabilitation intervention to
restore function, although the scope of this opportunity,
and specifics as to how rehabilitation would best be
carried out, remain to be seen. With earlier detection of
lung cancer, patients may have less debility from
chronic disease at the time of diagnosis and throughout
the course of treatment, although problems such as
post-thoracotomy pain and chemotherapy-induced
peripheral neuropathy are unlikely to be decreased. In
fact, more total patients may be diagnosed with lung
cancer, and therefore the number of patients in need of
rehabilitation services may increase. Postoperative
rehabilitation programs may be more effective in the
era of LDCT and earlier detection because of reduced
severity of chronic comorbidities, pain, and the need for
less extensive surgery. Although rehabilitation care for
lung cancer patients will doubtless change with the
advent of LDCT screening, a multimodal approach will
likely improve functional outcomes and possibly survival
if more patients are able to undergo surgery or have less
morbidity after surgery through prehabilitation and
rehabilitation.
With LDCT potentially resulting in more diagnoses at
cancer stages I and II, prehabilitation interventions may
play a significantly increased role, given that it has the
potential to prepare these patients for surgery and to
improve outcomes, including survival and the number of
patients who become suitable surgical candidates with a
prehabilitation regimen. What is unclear is whether
earlier detection would mean that patients would be
less impaired by deconditioning related to chronic dis-
ease. Modifications to preoperative conditioning regi-
mens may need to be made, such as shortening the
duration of a program, as disease detected earlier may
not require prehabilitation simply to prepare patients
for surgery if the cancer or underlying chronic condi-
tions such as COPD are not as advanced. More research
is needed to determine the optimal degree of rehabili-
tation intervention, as short- and long-term pre-
habilitation programs have not been directly compared,
nor have prehabilitation and postoperative rehabilita-
tion programs.
Given the success of even short-term prehabilitation
programs, and the significant impact of poor patient ex-
ercise capacity on postoperative hospital length of stay,
rehabilitation providers must evaluate interventions in
the context of cost savings; if a program reduces health
care costs, it is much more likely to be adopted by all
insurance payors. Prehabilitation in particular has the
potential to significantly support value-based careby reducing cost, improving surgical outcomes, and
improving patient satisfaction and HRQoL.
The subspecialty of cancer rehabilitation is experi-
encing rapid growth, due to both an increased number
of cancer survivors and renewed interest on behalf of
physiatry. It is imperative that physiatrists and other
members of the rehabilitation team to stay up-to-date
on oncology protocols such as the use of LDCT, and
explore opportunities to expand beneficial rehabilita-
tion services. Program development to accommodate
an increased number of patients, and to efficiently
manage these patients to reduce health care costs,
represents an opportunity to improve patient care,
expand the field, and research new avenues of
intervention.References
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